June 5, 2023 - NEOMATRIX CONCLUDES SUCCESSFUL FUNDRAISING TO SUPPORT DISCOVERY AND DEVELOMENT OF PERSONALIZED CANCER VACCINES.
The biotech Neomatrix today announced that it has closed a seed funding of EUR 2 millions led by 2Invest AG and i2i Capital Limited. The funds will be used to support discovery and development of personalized cancer vaccines based on innovative DNA technology ... (read more)
May 25, 2023 - 4basebio and Neomatrix announce clinical material supply agreement to develop personalised cancer therapy utilising 4basebio’s proprietary hpDNA™.
Cambridge, UK , 25 May 2023 – 4basebio PLC (AIM: 4BB), an innovation driven biotechnology company enabling and accelerating development of advanced therapy medicinal products (ATMPs) through its high performant synthetic DNA products ... (read more)
April 8, 2021 - Neomatrix awarded at BioinItaly Investment Forum.
Neomatrix awarded at BioinItaly Investment Forum
Neomatrix was among the four start-ups awarded at the “BioinItaly Investement Forum & Intesa San Paolo start up initiative” in the Life Sciences sector, with a novel personalized approach to ... (read more)
Seal of Excellence - EU Quality Label
Policy
Contact
-
Via di Castel Romano, 100
00128 Rome
© 2023 NEOMATRIX SRL | P. IVA 15698291000 | ALL RIGHTS RESERVED